Synthesis and Preclinical Evaluation of Novel 68 Ga-DOTA-RBB as Potential PET Radiotracer for Imaging CDK4/6 in Tumors

Zhen-Peng Yu,Xin Wang,Zhi-Qiang Yu,Hong Zhu,Jing-Xuan Miao,Hui Wang,Hongwei Si,Peng-Fei Dai
DOI: https://doi.org/10.1021/acsmedchemlett.4c00116
2024-06-19
ACS Medicinal Chemistry Letters
Abstract:Many malignant tumors, including breast cancer, exhibit amplification and overexpression of cyclin-dependent kinase 4 and 6 (CDK4/6). Ribociclib, approved and used in clinical treatment, acts as a highly selective CDK4/6 inhibitor for ER+/HER2- breast cancer. By modifying ribociclib with the chelator DOTA, we designed and synthesized a novel CDK4/6-positive PET imaging agent, which was radiolabeled by ^(68)Ga for radioactive tagging. The radiotracer demonstrates high radiochemical purity,...
chemistry, medicinal
What problem does this paper attempt to address?